tesamorelin/ipamorelin dosage: Frequently asked questions

Joint pain and carpal tunnel syndrome are GH-mediated side effects caused by fluid retention in synovial spaces and the carpal tunnel. Reduce your dose to 0.5mg Tesamorelin + 100mcg Ipamorelin for one week, then titrate back up slowly in 0.25mg increments weekly until symptoms resolve. These symptoms occur in approximately 15–20% of users at standard doses and 30–40% at escalated doses above 1.5mg + 300mcg. Lowering sodium intake below 2g daily and ensuring adequate hydration (3–4 litres water daily) reduces fluid retention severity. If symptoms persist at reduced dose, discontinue for two weeks and restart at the lowest effective dose. Some users require maintenance at 0.75mg + 150mcg rather than the standard 1mg + 200mcg.

No. Never double-dose peptides to 'make up' for a missed injection. Administer your regular 1mg Tesamorelin + 200mcg Ipamorelin dose at the next scheduled time and continue your normal protocol. Missing a single dose has minimal impact on overall body composition outcomes over a 24-week cycle; the GH elevation from Tesamorelin + Ipamorelin is cumulative, not acute. Doubling the dose creates a supraphysiological GH spike that increases fluid retention, joint pain, and carpal tunnel risk without improving fat loss or lean mass gain. If you miss doses frequently (more than twice weekly), the protocol's effectiveness diminishes. Consistency matters more than dose compensation.

GLP-1 receptor agonists (semaglutide, tirzepatide) and Tesamorelin + Ipamorelin are mechanistically complementary but create a practical protein intake challenge. GLP-1 medications suppress appetite and slow gastric emptying, making it harder to hit the 1.6–2.2g protein per kilogram threshold required for lean mass gain. Users combining both protocols should prioritise protein intake at every meal (minimum 30g complete protein per meal) and consider splitting Ipamorelin into two daily doses (100mcg fasted AM + 100mcg before bed) to maintain anabolic signalling despite reduced meal frequency. The peptide doses themselves don't require adjustment, but body composition monitoring should occur every four weeks rather than every 12 to ensure lean mass gain isn't stalling due to inadequate protein.

Drop tesamorelin dose to 0.5mg daily and maintain ipamorelin at current dose. Tesamorelin drives stronger GH elevation than ipamorelin, making it the primary contributor to insulin resistance. GH directly antagonises insulin signalling in hepatic and muscle tissue, which is why sustained supraphysiological GH can unmask latent glucose dysregulation. If glucose normalises within two weeks at reduced dose, you've found your individual tolerance threshold; if it remains elevated, discontinue tesamorelin entirely and consider ipamorelin monotherapy.

IGF-1 drops to pre-protocol levels within 10–14 days of stopping tesamorelin + ipamorelin, because you're augmenting endogenous production rather than replacing it with exogenous GH. This is markedly different from synthetic GH (somatropin), which suppresses natural production and requires 4–6 weeks for pituitary recovery. The rapid IGF-1 normalisation is why five-day-on, two-day-off cycling works. It prevents receptor downregulation without creating prolonged hypogonadotropic states.

Reduce tesamorelin dose by 25% immediately. These are classic signs of excess GH activity causing fluid retention in peripheral tissues. Joint pain from peptide protocols isn't the same as injury pain; it's extracellular fluid accumulation in joint capsules and tendon sheaths, which resolves within 5–7 days of dose reduction. If symptoms persist beyond one week at reduced dose, stop the protocol entirely and retest IGF-1. You may have baseline IGF-1 above 180 ng/mL, making exogenous GH augmentation unnecessary and potentially harmful.

Rotate injection sites across the entire abdomen, avoiding re-injection within 1 inch of a previous site for at least 72 hours. Persistent reactions suggest either localized lipohypertrophy from repeated trauma or sensitivity to benzyl alcohol in bacteriostatic water. Switching to sterile water for reconstitution eliminates the preservative but reduces shelf life to 5–7 days. If reactions continue with sterile water, consider alternating injection sites to the lateral thigh or upper arm. Severe reactions (spreading erythema, warmth, purulent drainage) indicate infection. Discontinue immediately and consult a physician.

Recomposition timelines vary based on baseline body composition, training stimulus, and dietary structure. If visceral fat and lean mass measurements show no change after 8 weeks, assess three factors: (1) injection timing relative to meals. GH release is blunted 30–50% if peptides are administered within 90 minutes of food intake; (2) storage integrity. Temperature excursions denature peptides without visible signs; (3) training and nutrition adherence. Peptides amplify the recomposition signal from resistance training and protein intake but do not replace them. Increasing dose above 1mg Tesamorelin + 300mcg Ipamorelin rarely resolves stalled progress and increases side effect likelihood.

Reduce dose to zero for one week, then restart at 75% of previous dose with strict evening timing (60 minutes pre-sleep, not 30). IGF-1 non-response typically indicates receptor saturation from improper titration or circadian misalignment. The peptides are working but the pituitary isn't responding because you've overridden its natural pulse rhythm. Retest IGF-1 at week 4 post-restart; if elevation remains below 20% of baseline, the issue is likely peptide purity or storage degradation rather than dosing strategy.

No. Never double-dose to compensate for a missed injection. Resume your regular schedule at the standard 1mg + 200–300mcg dose. Both peptides have short half-lives (Tesamorelin 26–38 minutes, Ipamorelin 2 hours), meaning a single missed dose does not create a cumulative deficit that requires correction. Doubling the dose elevates GH output beyond the effective threshold, increasing side effect risk (transient hyperglycemia, injection site reactions) without improving recomposition outcomes. Missing 1–2 doses per week has minimal impact on 16-week results.